Table 3.
Distribution of studies by quality-scoring values according to the Chalmers et al. and Jadad et al. methods
| Chalmers | Jadad score | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
First Author [Reference No.] |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
Protocol |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
19 |
20 |
21 |
22 |
Data analysis |
Overall |
1 |
2 |
3 |
Overall |
| Yenice [16] |
1 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0.17 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0.23 |
0.2 |
1 |
0 |
0 |
1 |
| Di Bisceglie [17] |
1 |
0 |
1 |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
n.a. |
0.35 |
0 |
1 |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
1 |
0 |
0.44 |
0.39 |
1 |
0 |
0 |
1 |
| Escudero [18] |
1 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0.11 |
1 |
1 |
0 |
0 |
1 |
1 |
0 |
1 |
0 |
1 |
0 |
0.61 |
0.31 |
0 |
0 |
0 |
0 |
| McHutchison [19] |
1 |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
1 |
1 |
0 |
0.58 |
1 |
1 |
0 |
0 |
1 |
1 |
0 |
1 |
0 |
1 |
0 |
0.61 |
0.6 |
2 |
0 |
1 |
3 |
| Ascione [20] |
1 |
1 |
1 |
1 |
0 |
0 |
0 |
1 |
1 |
1 |
0 |
0.54 |
1 |
1 |
0 |
n.a. |
1 |
1 |
0 |
1 |
0 |
1 |
0 |
0.67 |
0.59 |
2 |
0 |
1 |
3 |
| Lee [21] |
1 |
0 |
1 |
0 |
0 |
0 |
1 |
0 |
0 |
1 |
0 |
0.15 |
1 |
1 |
0 |
0 |
0 |
1 |
0 |
1 |
0 |
1 |
0 |
0.54 |
0.37 |
0 |
0 |
0 |
0 |
| Rumi [22] | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0.54 | 1 | 1 | 0 | n.a. | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0.67 | 0.59 | 2 | 0 | 1 | 3 |
For the Chalmers et al. method: 0 is “Non adequate”, 1 is “Adequate” for the following items: 1 Selection description; 2 Number and reasons for eligible patients not included in the study; 3 Regimen definition; 4 Blinding of Randomization; 5 Blinding of Patients to therapy; 6 Blinding of Physicians/observers to therapy; 7 Blinding of Physicians/observers to ongoing results; 8 Regimen definition; 9 Statistical estimate of sample size; 10 Testing randomization; 11 Testing compliance; 12 Dates of study; 13 Results of prerandomization; 14 Both test statistics and P value given; 15 Post beta estimate; 16 Confidence intervals given; 17 Regression/correlation; 18 Statistical analysis; 19 Number and reasons for patients withdrawn after randomization; 20 Withdrawals handled in several ways; 21 Side effects discussion; 22 Subgroups retrospective analysis. For the Jadad et al. the points are assigned for the following items: 1 Randomization; 2 Double-blinding; 3 Withdrawals and drop-out.
n.a. not applicable.